| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| GALD.SW - | BUY | 21,286 @ CHF 159.031 | CHF 3,385,134 | The ETF bought 21286 new shares of GALD.SW (). The shares were bought for an average price of 159.031 compared to the previous average buy price of 119.323. This is 33.3% higher than average price of previous purchases of GALD.SW. |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 48.72 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 48.72. The average price that SHL.DE shares were previous bought at was EUR 47.5402. The current market price is 2.5% higher than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 195,642 (USD $227,010) compared to the previous valuation of Siemens Healthineers AG |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 40.395 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 40.395. The average price that QIA.DE shares were previous bought at was EUR 39.7853. The current market price is 1.5% higher than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 116,305 (USD $134,953) compared to the previous valuation of QIAGEN NV |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 61.35 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 61.35. The average price that ORNBV.HE shares were previous bought at was EUR 59.6487. The current market price is 2.9% higher than average price they were purchased at. The value of the holding in ORNBV.HE has fallen by EUR 114,937 (USD $133,365) compared to the previous valuation of Orion Oyj |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 15.5431 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 15.5431. The average price that SN.L shares were previous bought at was GBP 13.5562. The current market price is 14.7% higher than average price they were purchased at. The value of the holding in SN.L has increased by GBP 9,872 (USD $13,026) compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2025-10-30 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 30.3956 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 30.3956. The average price that SOBI.ST shares were previous bought at was SEK 26.2071. The current market price is 16.0% higher than average price they were purchased at. The value of the holding in SOBI.ST has increased by SEK 64,610 (USD $6,870) compared to the previous valuation of however if the holding was sold on 2025-10-30 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 112.55 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 112.55. The average price that MRK.DE shares were previous bought at was EUR 118.15. The current market price is -4.7% lower than average price they were purchased at. The value of the holding in MRK.DE has fallen by EUR 284,825 (USD $330,492) compared to the previous valuation of Merck KGaA |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 122.3 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 122.3. The average price that IPN.PA shares were previous bought at was EUR 108.264. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 10,385 (USD $12,050) compared to the previous valuation of Ipsen SA however if the holding was sold on 2025-10-30 this would crystalise an overall loss. |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 51.55 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 51.55. The average price that REC.MI shares were previous bought at was EUR 52.8674. The current market price is -2.5% lower than average price they were purchased at. The value of the holding in REC.MI has increased by EUR 79,113 (USD $91,798) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA however if the holding was sold on 2025-10-30 this would crystalise an overall loss. |
| HIK.L - | HOLD | 0 @ GBP 20.7279 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 20.7279. The average price that HIK.L shares were previous bought at was GBP 22.9479. The current market price is -9.7% lower than average price they were purchased at. The value of the holding in HIK.L has increased by GBP 4,961 (USD $6,546) compared to the previous valuation of however if the holding was sold on 2025-10-30 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 236.7 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 236.7. The average price that SRT3.DE shares were previous bought at was EUR 214.574. The current market price is 10.3% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 74,732 (USD $86,714) compared to the previous valuation of Sartorius AG |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 11.355 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 11.355. The average price that GRF.MC shares were previous bought at was EUR 10.6762. The current market price is 6.4% higher than average price they were purchased at. The value of the holding in GRF.MC has fallen by EUR 19,051 (USD $22,106) compared to the previous valuation of Grifols SA |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 46.61 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 46.61. The average price that FME.DE shares were previous bought at was EUR 46.6203. The current market price is 0.0% lower than average price they were purchased at. The value of the holding in FME.DE has fallen by EUR 42,500 (USD $49,314) compared to the previous valuation of Fresenius Medical Care AG |
| RO.SW - | HOLD | 0 @ CHF 295.852 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 295.852. The average price that RO.SW shares were previous bought at was CHF 301.312. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 57,914 (USD $72,411) compared to the previous valuation of however if the holding was sold on 2025-10-30 this would crystalise an overall loss. |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 206.8 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 206.8. The average price that DIM.PA shares were previous bought at was EUR 192.42. The current market price is 7.5% higher than average price they were purchased at. The value of the holding in DIM.PA has fallen by EUR 56,429 (USD $65,477) compared to the previous valuation of Sartorius Stedim Biotech |
| DEMANT.CO - | HOLD | 0 @ DKK 29.2231 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 29.2231. The average price that DEMANT.CO shares were previous bought at was DKK 34.3141. The current market price is -14.8% lower than average price they were purchased at. The value of the holding in DEMANT.CO has fallen by DKK 68,398 (USD $10,627) compared to the previous valuation of |
| COLO-B.CO - | HOLD | 0 @ DKK 78.9371 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 78.9371. The average price that COLO-B.CO shares were previous bought at was DKK 83.8073. The current market price is -5.8% lower than average price they were purchased at. The value of the holding in COLO-B.CO has fallen by DKK 62,609 (USD $9,728) compared to the previous valuation of |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 110.7 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 110.7. The average price that BIM.PA shares were previous bought at was EUR 115.151. The current market price is -3.9% lower than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 49,044 (USD $56,907) compared to the previous valuation of BioMerieux |
| BAYN.DE - Bayer AG | SELL | -2,506 @ EUR 26.87 | EUR -67,336 | The ETF sold 2506 shares of BAYN.DE on 2025-10-30. The shares were previously bought for an average price of EUR 25.023. The Bayer AG shares were sold for 7.4% higher than average price of previous purchases. This sale made a profit of EUR 4,629 (USD $5,371) The average price that the ETF previously sold BAYN.DE share for is EUR 21.9878 so the ETF has sold 2506 shares on 2025-10-30 at a higher price than the previous selling average. |
| SOON.SW - | SELL | -285 @ CHF 236.876 | CHF -67,510 | The ETF sold 285 shares of SOON.SW on 2025-10-30. The shares were previously bought for an average price of CHF 265.705. The shares were sold for -10.9% lower than average price of previous purchases. This resulted in an overall loss of CHF 8,216 (USD $10,273) The average price that the ETF previously sold SOON.SW share for is CHF 298.818 which is higher than the selling price of CHF 236.876 on 2025-10-30. |
| GMAB.CO - | SELL | -275 @ DKK 246.36 | DKK -67,749 | The ETF sold 275 shares of GMAB.CO on 2025-10-30. The shares were previously bought for an average price of DKK 201.572. The shares were sold for 22.2% higher than average price of previous purchases. This sale made a profit of DKK 12,317 (USD $1,914) The average price that the ETF previously sold GMAB.CO share for is DKK 189.963 so the ETF has sold 275 shares on 2025-10-30 at a higher price than the previous selling average. |
| ERF.PA - Eurofins Scientific SE | SELL | -1,128 @ EUR 60.62 | EUR -68,379 | The ETF sold 1128 shares of ERF.PA on 2025-10-30. The shares were previously bought for an average price of EUR 57.4463. The Eurofins Scientific SE shares were sold for 5.5% higher than average price of previous purchases. This sale made a profit of EUR 3,580 (USD $4,154) The average price that the ETF previously sold ERF.PA share for is EUR 53.1956 so the ETF has sold 1128 shares on 2025-10-30 at a higher price than the previous selling average. |
| PHIA.AS - Koninklijke Philips NV | SELL | -2,944 @ EUR 23.73 | EUR -69,861 | The ETF sold 2944 shares of PHIA.AS on 2025-10-30. The shares were previously bought for an average price of EUR 22.0475. The Koninklijke Philips NV shares were sold for 7.6% higher than average price of previous purchases. This sale made a profit of EUR 4,953 (USD $5,748) The average price that the ETF previously sold PHIA.AS share for is EUR 23.0611 so the ETF has sold 2944 shares on 2025-10-30 at a higher price than the previous selling average. |
| FRE.DE - Fresenius SE & Co KGaA | SELL | -1,409 @ EUR 50.36 | EUR -70,957 | The ETF sold 1409 shares of FRE.DE on 2025-10-30. The shares were previously bought for an average price of EUR 41.786. The Fresenius SE & Co KGaA shares were sold for 20.5% higher than average price of previous purchases. This sale made a profit of EUR 12,081 (USD $14,018) The average price that the ETF previously sold FRE.DE share for is EUR 39.6544 so the ETF has sold 1409 shares on 2025-10-30 at a higher price than the previous selling average. |
| ALC.SW - | SELL | -1,126 @ CHF 64.4104 | CHF -72,526 | The ETF sold 1126 shares of ALC.SW on 2025-10-30. The shares were previously bought for an average price of CHF 74.9308. The shares were sold for -14.0% lower than average price of previous purchases. This resulted in an overall loss of CHF 11,846 (USD $14,811) The average price that the ETF previously sold ALC.SW share for is CHF 79.3623 which is higher than the selling price of CHF 64.4104 on 2025-10-30. |
| SDZ.SW - | SELL | -1,279 @ CHF 57.0356 | CHF -72,949 | The ETF sold 1279 shares of SDZ.SW on 2025-10-30. The shares were previously bought for an average price of CHF 45.0695. The shares were sold for 26.6% higher than average price of previous purchases. This sale made a profit of CHF 15,305 (USD $19,136) The average price that the ETF previously sold SDZ.SW share for is CHF 42.4741 so the ETF has sold 1279 shares on 2025-10-30 at a higher price than the previous selling average. |
| STMN.SW - | SELL | -726 @ CHF 104.497 | CHF -75,865 | The ETF sold 726 shares of STMN.SW on 2025-10-30. The shares were previously bought for an average price of CHF 110.275. The shares were sold for -5.2% lower than average price of previous purchases. This resulted in an overall loss of CHF 4,195 (USD $5,245) The average price that the ETF previously sold STMN.SW share for is CHF 116.097 which is higher than the selling price of CHF 104.497 on 2025-10-30. |
| HLN.L - Haleon PLC | SELL | -20,006 @ GBP 3.98867 | GBP -79,797 | The ETF sold 20006 shares of HLN.L on 2025-10-30. The shares were previously bought for an average price of GBP 4.43181. The Haleon PLC shares were sold for -10.0% lower than average price of previous purchases. This resulted in an overall loss of GBP 8,865 (USD $11,698) The average price that the ETF previously sold HLN.L share for is GBP 4.61763 which is higher than the selling price of GBP 3.98867 on 2025-10-30. |
| ARGX.BR - Argenx SE | SELL | -119 @ EUR 702.4 | EUR -83,586 | The ETF sold 119 shares of ARGX.BR on 2025-10-30. The shares were previously bought for an average price of EUR 555.279. The Argenx SE shares were sold for 26.5% higher than average price of previous purchases. This sale made a profit of EUR 17,507 (USD $20,314) The average price that the ETF previously sold ARGX.BR share for is EUR 552.605 so the ETF has sold 119 shares on 2025-10-30 at a higher price than the previous selling average. |
| UCB.BR - UCB SA | SELL | -362 @ EUR 237.6 | EUR -86,011 | The ETF sold 362 shares of UCB.BR on 2025-10-30. The shares were previously bought for an average price of EUR 184.168. The UCB SA shares were sold for 29.0% higher than average price of previous purchases. This sale made a profit of EUR 19,342 (USD $22,444) The average price that the ETF previously sold UCB.BR share for is EUR 173.311 so the ETF has sold 362 shares on 2025-10-30 at a higher price than the previous selling average. |
| LONN.SW - | SELL | -143 @ CHF 602.055 | CHF -86,094 | The ETF sold 143 shares of LONN.SW on 2025-10-30. The shares were previously bought for an average price of CHF 604.809. The shares were sold for -0.5% lower than average price of previous purchases. This resulted in an overall loss of CHF 394 (USD $493) The average price that the ETF previously sold LONN.SW share for is CHF 586.73 so the ETF has sold 143 shares on 2025-10-30 at a higher price than the previous selling average. |
| GSK.L - GlaxoSmithKline PLC | SELL | -9,157 @ GBP 20.2731 | GBP -185,641 | The ETF sold 9157 shares of GSK.L on 2025-10-30. The shares were previously bought for an average price of GBP 16.9621. The GlaxoSmithKline PLC shares were sold for 19.5% higher than average price of previous purchases. This sale made a profit of GBP 30,319 (USD $40,007) The average price that the ETF previously sold GSK.L share for is GBP 16.6812 so the ETF has sold 9157 shares on 2025-10-30 at a higher price than the previous selling average. |
| SAN.PA - Sanofi SA | SELL | -2,461 @ EUR 88.07 | EUR -216,740 | The ETF sold 2461 shares of SAN.PA on 2025-10-30. The shares were previously bought for an average price of EUR 86.8979. The Sanofi SA shares were sold for 1.3% higher than average price of previous purchases. This sale made a profit of EUR 2,885 (USD $3,347) The average price that the ETF previously sold SAN.PA share for is EUR 92.608 which is higher than the selling price of EUR 88.07 on 2025-10-30. |
| EL.PA - EssilorLuxottica SA | SELL | -736 @ EUR 319.5 | EUR -235,152 | The ETF sold 736 shares of EL.PA on 2025-10-30. The shares were previously bought for an average price of EUR 255.954. The EssilorLuxottica SA shares were sold for 24.8% higher than average price of previous purchases. This sale made a profit of EUR 46,770 (USD $54,269) The average price that the ETF previously sold EL.PA share for is EUR 254.877 so the ETF has sold 736 shares on 2025-10-30 at a higher price than the previous selling average. |
| NOVO-B.CO - Novo Nordisk A/S | SELL | -7,209 @ DKK 43.2185 | DKK -311,562 | The ETF sold 7209 shares of NOVO-B.CO on 2025-10-30. The shares were previously bought for an average price of DKK 56.2282. The Novo Nordisk A/S shares were sold for -23.1% lower than average price of previous purchases. This resulted in an overall loss of DKK 93,787 (USD $14,572) The average price that the ETF previously sold NOVO-B.CO share for is DKK 57.7039 which is higher than the selling price of DKK 43.2185 on 2025-10-30. |
| ROG.SW - | SELL | -1,578 @ CHF 282.159 | CHF -445,247 | The ETF sold 1578 shares of ROG.SW on 2025-10-30. The shares were previously bought for an average price of CHF 285.999. The shares were sold for -1.3% lower than average price of previous purchases. This resulted in an overall loss of CHF 6,060 (USD $7,576) The average price that the ETF previously sold ROG.SW share for is CHF 279.856 so the ETF has sold 1578 shares on 2025-10-30 at a higher price than the previous selling average. |
| NOVN.SW - | SELL | -4,314 @ CHF 106.61 | CHF -459,916 | The ETF sold 4314 shares of NOVN.SW on 2025-10-30. The shares were previously bought for an average price of CHF 103.22. The shares were sold for 3.3% higher than average price of previous purchases. This sale made a profit of CHF 14,624 (USD $18,284) The average price that the ETF previously sold NOVN.SW share for is CHF 100.029 so the ETF has sold 4314 shares on 2025-10-30 at a higher price than the previous selling average. |
| AZN.L - AstraZeneca PLC | SELL | -3,401 @ GBP 142.651 | GBP -485,156 | The ETF sold 3401 shares of AZN.L on 2025-10-30. The shares were previously bought for an average price of GBP 129.624. The AstraZeneca PLC shares were sold for 10.0% higher than average price of previous purchases. This sale made a profit of GBP 44,305 (USD $58,460) The average price that the ETF previously sold AZN.L share for is GBP 126.862 so the ETF has sold 3401 shares on 2025-10-30 at a higher price than the previous selling average. |